Item 2.02 Results of Operations and Financial Condition. On April 6, 2026, Sunshine Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for the year ended December 31, 2025. The press release is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
SBFM Sunshine Biopharma, Inc - 8-K
Accession
0001683168-26-0027812.029.01
Item 2.02 - Results of Operations and Financial Condition
Earnings press release item. The actual results are typically in Exhibit 99.1 - fetch may not have completed.
Item 9.01 - Financial Statements and Exhibits
26 words
Item 9.01 Financial Statements and Exhibits. Exhibit No . Description 99.1 Press Release 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2